CTMX vs PBYI vs RCUS vs NKTR

For growth investors, Puma Biotechnology, Inc.

(PBYI) is the stronger pick with -0. 9% revenue growth year-over-year, versus -44. 8% for CytomX Therapeutics, Inc. (CTMX). Puma Biotechnology, Inc. (PBYI) offers the better valuation at 11. 9x trailing P/E (29. 0x forward), making it the more compelling value choice. Analysts rate CytomX Therapeutics, Inc. (CTMX) a "Buy" — based on 21 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Arcus Biosciences, Inc.

(RCUS) delivered a total return of -18. 6%, compared to -72. 3% for Nektar Therapeutics (NKTR). Over 10 years, the gap is even starker: RCUS returned +45. 9% versus PBYI's -70. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Puma Biotechnology, Inc.

(PBYI) is the lower-risk stock at 1. 11β versus Arcus Biosciences, Inc. 's 1. 95β — meaning RCUS is approximately 76% more volatile than PBYI relative to the S&P 500. On balance sheet safety, CytomX Therapeutics, Inc. (CTMX) carries a lower debt/equity ratio of 4% versus 166% for Nektar Therapeutics — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Puma Biotechnology, Inc.

(PBYI) is pulling ahead at -0. 9% versus -44. 8% for CytomX Therapeutics, Inc. (CTMX). On earnings-per-share growth, the picture is similar: Puma Biotechnology, Inc. grew EPS -1. 6% year-over-year, compared to -139. 5% for CytomX Therapeutics, Inc.. Over a 3-year CAGR, RCUS leads at 30. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Puma Biotechnology, Inc.

(PBYI) is the more profitable company, earning 13. 6% net margin versus -297. 1% for Nektar Therapeutics — meaning it keeps 13. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PBYI leads at 16. 3% versus -236. 8% for NKTR. At the gross margin level — before operating expenses — CTMX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for CTMX: 190.

0% to $11. 60.

In this comparison, CTMX (0.

5% yield) pays a dividend. PBYI, RCUS, NKTR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, CytomX Therapeutics, Inc.

(CTMX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (0. 5% yield). Arcus Biosciences, Inc. (RCUS) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CTMX: -66. 9%, RCUS: +45. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CTMX is a small-cap quality compounder stock; PBYI is a small-cap deep-value stock; RCUS is a small-cap quality compounder stock; NKTR is a small-cap quality compounder stock. CTMX pays a dividend while PBYI, RCUS, NKTR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.